Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 3/20 | 0.32 |
| ▸ | TDO2 | P48775 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164259 | 0.83 | CRHR1 (0.33) | — | |
| SCHEMBL4160444 | 0.80 | — | — | |
| SCHEMBL4166669 | 0.78 | ALDH1A1 (0.34) | LMNAHSD17B10TSHR | |
| SCHEMBL4165752 | 0.75 | CRHR1 (0.32) | L3MBTL1 | |
| SCHEMBL4170000 | 0.69 | CRHR1 (0.43) | LMNA | |
| SCHEMBL4158630 | 0.67 | TSHR (0.31) | L3MBTL1MAPTTSHR | |
| SCHEMBL4171837 | 0.63 | HDAC1 (0.36) | — | |
| SCHEMBL17628629 | 0.63 | SRC (0.34) | LMNATSHR | |
| SCHEMBL10324182 | 0.62 | SRC (0.34) | — | |
| SCHEMBL6859743 | 0.61 | ADORA2A (0.43) | EGFRTOP2ATOP2BMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105261-A1 | Novel substituted pyrazolo[1,5<I>A</I>]-1,3,5-Triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | GREENPHARMA (FR) | 2009-04-23 | — | — | US | claimed |
| US-20060106019-A1 | Novel substituted pyrazolo[1,5 a]-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | GREENPHARMA (FR) | 2006-05-18 | — | — | US | claimed |
| US-20090105261-A1 | Novel substituted pyrazolo[1,5<I>A</I>]-1,3,5-Triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | GREENPHARMA (FR) | 2009-04-23 | — | — | US | disclosed |
| US-20060106019-A1 | Novel substituted pyrazolo[1,5 a]-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | GREENPHARMA (FR) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106019-A1 | Novel substituted pyrazolo[1,5 a]-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | PMP22, BDNF, GRIK5 | EGFR 3894/4885TOP2A 2126/4885TOP2B 1930/4885 |
| US-20090105261-A1 | Novel substituted pyrazolo[1,5<I>A</I>]-1,3,5-Triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | BDNF, NTRK2, NGF | EGFR 453/4885TOP2A 3976/4885TOP2B 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.